Chartwell Investment Partners’s Myriad Genetics MYGN Stock Holding History

Chartwell Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35,866	Closed	-$996K	–	414
2019 Q2	$996K	Sell	35,866 -3,530	-9%	-$99.7K	0.03%	381
2019 Q1	$1.31M	Sell	39,396 -671	-2%	-$20.4K	0.04%	373
2018 Q4	$1.17M	Buy	40,067 +276	+0.7%	+$9.93K	0.04%	393
2018 Q3	$1.83M	Sell	39,791 -3,725	-9%	-$166K	0.05%	398
2018 Q2	$1.63M	Sell	43,516 -1,025	-2%	-$34.6K	0.05%	401
2018 Q1	$1.32M	Sell	44,541 -76,005	-63%	-$2.57M	0.05%	349
2017 Q4	$4.14M	Buy	120,546 +28,831	+31%	+$973K	0.14%	230
2017 Q3	$3.32M	Sell	91,715 -61,000	-40%	-$1.74M	0.11%	251
2017 Q2	$3.95M	Hold	152,715	–	–	0.15%	191
2017 Q1	$2.93M	Buy	152,715 +33,000	+28%	+$585K	0.11%	236
2016 Q4	$2M	Hold	119,715	–	–	0.07%	313
2016 Q3	$2.46M	Buy	119,715 +35,000	+41%	+$888K	0.04%	331
2016 Q2	$2.59M	Buy	+84,715	New	+$2.94M	0.05%	304

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Chartwell Investment Partners's MYGN Position: Q3 2019 in Review

Chartwell Investment Partners sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 35,866 shares — an estimated $996K sold.

Chartwell Investment Partners first reported a position in MYGN in Q2 2016 and held it in 13 quarters. The position peaked at $4.14M in Q4 2017. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Chartwell Investment Partners reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Chartwell Investment Partners sold 35,866 Myriad Genetics shares in Q3 2019, an estimated $996K.
Chartwell Investment Partners first reported a position in Myriad Genetics in Q2 2016 and held it in 13 quarters.
Chartwell Investment Partners's Myriad Genetics position peaked at $4.14M in Q4 2017.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Chartwell Investment Partners's 13F filing for Q3 2019, filed 29 Oct 2019.